148 related articles for article (PubMed ID: 16788002)
1. Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling.
Tournilhac O; Santos DD; Xu L; Kutok J; Tai YT; Le Gouill S; Catley L; Hunter Z; Branagan AR; Boyce JA; Munshi N; Anderson KC; Treon SP
Ann Oncol; 2006 Aug; 17(8):1275-82. PubMed ID: 16788002
[TBL] [Abstract][Full Text] [Related]
2. Clinical, Laboratory, and Bone Marrow Findings of 31 Patients With Waldenström Macroglobulinemia.
Ahn A; Park CJ; Cho YU; Jang S; Seo EJ; Lee JH; Yoon DH; Suh C
Ann Lab Med; 2020 May; 40(3):193-200. PubMed ID: 31858758
[TBL] [Abstract][Full Text] [Related]
3. CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders.
Santos DD; Hatjiharissi E; Tournilhac O; Chemaly MZ; Leleu X; Xu L; Patterson C; Branagan AR; Manning RJ; Ho AW; Hunter ZR; Dimmock EA; Kutok JL; Churchill WH; Castells MC; Tai YT; Anderson KC; Treon SP
Clin Lymphoma Myeloma; 2006 May; 6(6):478-83. PubMed ID: 16796779
[TBL] [Abstract][Full Text] [Related]
4. Mast cells (MC) excess in a bone marrow (BM) associated with lymphoplasmacytic cells (LPC) in a 55-Y-old patient with Waldenström's macroglobulinemia (WM).
Gentelet M; Demulder A
Ann Biol Clin (Paris); 2021 Feb; 79(1):92-93. PubMed ID: 33527905
[No Abstract] [Full Text] [Related]
5. CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia.
Ho AW; Hatjiharissi E; Ciccarelli BT; Branagan AR; Hunter ZR; Leleu X; Tournilhac O; Xu L; O'Connor K; Manning RJ; Santos DD; Chemaly M; Patterson CJ; Soumerai JD; Munshi NC; McEarchern JA; Law CL; Grewal IS; Treon SP
Blood; 2008 Dec; 112(12):4683-9. PubMed ID: 18216294
[TBL] [Abstract][Full Text] [Related]
6. Mast cell density and its clinical relevance in Waldenström's macroglobulinemia.
Lemal R; Poulain S; Ledoux-Pilon A; Veronese L; Tchirkov A; Lebecque B; Tassin T; Bay JO; Charlotte F; Nguyen-Khac F; Berger M; Godfraind C; Ysebaert L; Davi F; Pereira B; Leblond V; Hermine O; Guièze R; Pagès F; Tournilhac O
EJHaem; 2022 May; 3(2):371-378. PubMed ID: 35846063
[TBL] [Abstract][Full Text] [Related]
7. Targeting CD40 in Waldenström's macroglobulinemia.
Lee M; Advani R
Clin Lymphoma Myeloma; 2009 Mar; 9(1):87-9. PubMed ID: 19362983
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow microenvironment in Waldenstrom's Macroglobulinemia.
Jalali S; Ansell SM
Best Pract Res Clin Haematol; 2016 Jun; 29(2):148-155. PubMed ID: 27825460
[TBL] [Abstract][Full Text] [Related]
9. Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice.
Ditzel Santos D; Ho AW; Tournilhac O; Hatjiharissi E; Leleu X; Xu L; Tassone P; Neri P; Hunter ZR; Chemaly MA; Branagan AR; Manning RJ; Patterson CJ; Moreau AS; Ciccarelli B; Adamia S; Kriangkum J; Kutok JL; Tai YT; Zhang J; Pilarski LM; Anderson KC; Munshi N; Treon SP
Exp Hematol; 2007 Sep; 35(9):1366-75. PubMed ID: 17761288
[TBL] [Abstract][Full Text] [Related]
10. Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenström's macroglobulinemia.
Morice WG; Chen D; Kurtin PJ; Hanson CA; McPhail ED
Mod Pathol; 2009 Jun; 22(6):807-16. PubMed ID: 19287458
[TBL] [Abstract][Full Text] [Related]
11. Clonal B cells in Waldenström's macroglobulinemia exhibit functional features of chronic active B-cell receptor signaling.
Argyropoulos KV; Vogel R; Ziegler C; Altan-Bonnet G; Velardi E; Calafiore M; Dogan A; Arcila M; Patel M; Knapp K; Mallek C; Hunter ZR; Treon SP; van den Brink MR; Palomba ML
Leukemia; 2016 May; 30(5):1116-25. PubMed ID: 26867669
[TBL] [Abstract][Full Text] [Related]
12. Immunophenotypic analysis of Waldenstrom's macroglobulinemia.
San Miguel JF; Vidriales MB; Ocio E; Mateo G; Sánchez-Guijo F; Sánchez ML; Escribano L; Bárez A; Moro MJ; Hernández J; Aguilera C; Cuello R; García-Frade J; López R; Portero J; Orfao A
Semin Oncol; 2003 Apr; 30(2):187-95. PubMed ID: 12720134
[TBL] [Abstract][Full Text] [Related]
13. Novel agents in the treatment of Waldenström's macroglobulinemia.
Treon SP; Hatjiharissi E; Leleu X; Moreau AS; Roccaro A; Hunter ZR; Soumerai JD; Ciccarelli B; Xu L; Sacco A; Ngo HT; Jia X; Yang C; Adamia S; Branagan AR; Ho AW; Santos DD; Tournilhac O; Manning RJ; Leduc R; O'Connor K; Nelson M; Patterson CJ; Ghobrial I
Clin Lymphoma Myeloma; 2007 Aug; 7 Suppl 5():S199-206. PubMed ID: 17877845
[TBL] [Abstract][Full Text] [Related]
14. Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia.
Sacco A; Aujay M; Morgan B; Azab AK; Maiso P; Liu Y; Zhang Y; Azab F; Ngo HT; Issa GC; Quang P; Roccaro AM; Ghobrial IM
Clin Cancer Res; 2011 Apr; 17(7):1753-64. PubMed ID: 21355079
[TBL] [Abstract][Full Text] [Related]
15. Autoimmune thrombocytopenia: flow cytometric determination of platelet-associated CD154/CD40L and CD40 on peripheral blood T and B lymphocytes.
Meabed MH; Taha GM; Mohamed SO; El-Hadidy KS
Hematology; 2007 Aug; 12(4):301-7. PubMed ID: 17654056
[TBL] [Abstract][Full Text] [Related]
16. The bone marrow microenvironment in Waldenström macroglobulinemia.
Agarwal A; Ghobrial IM
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):218-21. PubMed ID: 23490994
[TBL] [Abstract][Full Text] [Related]
17. Targeting the immune microenvironment in Waldenström macroglobulinemia via halting the CD40/CD40-ligand axis.
Sacco A; Desantis V; Celay J; Giustini V; Rigali F; Savino FD; Cea M; Soncini D; Cagnetta A; Solimando AG; D'Aliberti D; Spinelli S; Ramazzotti D; Almici C; Todoerti K; Neri A; Anastasia A; Tucci A; Motta M; Chiarini M; Kawano Y; Martinez-Climent JA; Piazza R; Roccaro AM
Blood; 2023 May; 141(21):2615-2628. PubMed ID: 36735903
[TBL] [Abstract][Full Text] [Related]
18. Sequence and expression analyses of mu and delta transcripts in patients with Waldenström's macroglobulinemia.
Shiokawa S; Suehiro Y; Uike N; Muta K; Nishimura J
Am J Hematol; 2001 Nov; 68(3):139-43. PubMed ID: 11754393
[TBL] [Abstract][Full Text] [Related]
19. Clone-specific MYD88 L265P and CXCR4 mutation status can provide clinical utility in suspected Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
Burnworth B; Wang Z; Singleton TP; Bennington A; Fritschle W; Bennington R; Brodersen LE; Wells DA; Loken MR; Zehentner BK
Leuk Res; 2016 Dec; 51():41-48. PubMed ID: 27890075
[TBL] [Abstract][Full Text] [Related]
20. CD154-CD40 interactions in the control of murine B cell hematopoiesis.
Carlring J; Altaher HM; Clark S; Chen X; Latimer SL; Jenner T; Buckle AM; Heath AW
J Leukoc Biol; 2011 May; 89(5):697-706. PubMed ID: 21330346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
